Precision medicine (PM) is a medical concept that recommends tailoring healthcare by customizing medical decisions, treatments, techniques, or products to a subset of patients rather than using a one-drug-fits-all approach. Diagnostic testing is frequently used in precision medicine to determine appropriate and optimal therapeutics based on a patient's genetic content or other molecular analysis. Although the term 'personalized medicine' is frequently used to represent this idea, it is sometimes misinterpreted to mean that specific therapies may be tailored to each individual.
As the specialty drug pipeline grows and expands, the definition of a specialty drug continues to shift. Specialty drugs are high-priced prescription medications used to treat complex, long-term illnesses such as cancer. Specialty medications may necessitate unique handling and administration (typically injection or infusion).
- Personalized drugs and therapies
- Market Strategies & Challenges in Personalized Medicine
- Treating disease with Specialty Drugs
- Specialty Pharmacy
Luis Jesus Villarreal Gomez
FCITEC - Universidad Autónoma de Baja California, Mexico
Thomas J. Webster
School of Health Sciences and Biomedical Engineering and Mansfield Bioincubator, China
Miroslav Radenkovic
University of Belgrade, Serbia
A C Matin
Stanford University, United States
Luis Jesus Villarreal Gomez
FCITEC - Universidad Autónoma de Baja California, Mexico
Miroslav Radenkovic
University of Belgrade, Serbia
A C Matin
Stanford University, United States
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Andreas M Papas
Antares Health Products, United States
Consolato M Sergi
University of Ottawa, CanadaSubmit your abstract Today
Title : Nanomaterial-mediated systemically administered m-RNA-based gene therapy directed exclusively to cancer, present successes and future prospects
A C Matin, Stanford University, United States
Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, and upgraded business modeling to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Preparation and characterization of fibers crafted from PCL/PVP-ChAgG, coupled with investigating their suitability as wound dressings.
Luis Jesus Villarreal Gomez, FCITEC - Universidad Autónoma de Baja California, Mexico
Title : Is your drug delivery formulation harming the environment ? Approaches to both save human health and the environment
Thomas J. Webster, School of Health Sciences and Biomedical Engineering and Mansfield Bioincubator, China
Title : Clinical pharmacology of aprocitentan (an endothelin receptor antagonist) – The most recent quality progress in treatment of resistant hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Clinical decision making in advanced and metastatic breast cancer cases between PARP inhibitors and CDK4/6 inhibitors
Priya Hays, Hays Documentation Specialists, LLC, United States
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Novel nano drug platform for pharmacologically inducing therapeutic hypothermia (TH) after traumatic brain injury (TBI)
Jorge David Tovar Castro, University of Miami Miller School of Medicine, United States
Title : Global drug development - Trends, challenges and opportunities
Gurpreet Singh, IQVIA, United Kingdom
Title : Drug design for the development of long-acting injectables
Thomas Ullrich, Novartis Biomedical Research, Switzerland